• レポートコード:QFJ1-5567 • 出版社/出版日:QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態:英文、PDF、95ページ • 納品方法:Eメール(納期:3日) • 産業分類:医薬品 |
Single User | ¥585,000 (USD3,900) | ▷ お問い合わせ |
Multi User | ¥877,500 (USD5,850) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
QYResearch社発行の本調査レポートでは、副腎皮質がん用治療薬の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(化学療法、標的療法)、用途別市場規模(病院、研究機関、診療所、その他)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。 ・市場概要 ・副腎皮質がん用治療薬の市場動向 ・企業の競争状況、市場シェア ・副腎皮質がん用治療薬の種類別市場規模と予測2016-2027(化学療法、標的療法) ・副腎皮質がん用治療薬の用途別市場規模と予測2016-2027(病院、研究機関、診療所、その他) ・副腎皮質がん用治療薬の北米市場規模2016-2027(アメリカ、カナダ) ・副腎皮質がん用治療薬の欧州市場規模2016-2027(ドイツ、フランス、イギリス等) ・副腎皮質がん用治療薬のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等) ・副腎皮質がん用治療薬の中南米市場規模2016-2027(メキシコ、ブラジル) ・副腎皮質がん用治療薬の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等) ・主要企業情報(Bristol-Myers Squibb Co.、Eli Lilly and Co.、Laboratoire HRA Pharma SAS、Progenics Pharmaceuticals Inc.、Teva Pharmaceutical Industries Ltd.) ・結論 |
The adrenocortical carcinoma drugs market has recorded the development of several advanced imaging techniques, which are non-invasive and exhibit enhanced diagnostic accuracy in the detection of adrenal lesions.
For instance, unenhanced computed tomography adrenal densitometry is used to differentiate adrenal adenomas from malignant lesions based on the presence of intracellular lipids. A combination of positron emission tomography/computed tomography is also gaining popularity among end-users for the identification of malignant and benign lesions. Similarly, multiphase computed tomography technique is being used to calculate absolute and relative percentage washout, and thereby, differentiate between benign and malignant lesions.
Market Analysis and Insights: Global Adrenocortical Carcinoma Drugs Market
The global Adrenocortical Carcinoma Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Adrenocortical Carcinoma Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Adrenocortical Carcinoma Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Adrenocortical Carcinoma Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Adrenocortical Carcinoma Drugs market.
Global Adrenocortical Carcinoma Drugs Scope and Market Size
Adrenocortical Carcinoma Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Adrenocortical Carcinoma Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Chemotherapy
Targeted therapy
Segment by Application
Hospital
Research institute
Clinic
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Bristol-Myers Squibb Co.
Eli Lilly and Co.
Laboratoire HRA Pharma SAS
Progenics Pharmaceuticals Inc.
Teva Pharmaceutical Industries Ltd.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Adrenocortical Carcinoma Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Chemotherapy
1.2.3 Targeted therapy
1.3 Market by Application
1.3.1 Global Adrenocortical Carcinoma Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Research institute
1.3.4 Clinic
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Adrenocortical Carcinoma Drugs Market Perspective (2016-2027)
2.2 Adrenocortical Carcinoma Drugs Growth Trends by Regions
2.2.1 Adrenocortical Carcinoma Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Adrenocortical Carcinoma Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Adrenocortical Carcinoma Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Adrenocortical Carcinoma Drugs Industry Dynamic
2.3.1 Adrenocortical Carcinoma Drugs Market Trends
2.3.2 Adrenocortical Carcinoma Drugs Market Drivers
2.3.3 Adrenocortical Carcinoma Drugs Market Challenges
2.3.4 Adrenocortical Carcinoma Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Adrenocortical Carcinoma Drugs Players by Revenue
3.1.1 Global Top Adrenocortical Carcinoma Drugs Players by Revenue (2016-2021)
3.1.2 Global Adrenocortical Carcinoma Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Adrenocortical Carcinoma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Adrenocortical Carcinoma Drugs Revenue
3.4 Global Adrenocortical Carcinoma Drugs Market Concentration Ratio
3.4.1 Global Adrenocortical Carcinoma Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Adrenocortical Carcinoma Drugs Revenue in 2020
3.5 Adrenocortical Carcinoma Drugs Key Players Head office and Area Served
3.6 Key Players Adrenocortical Carcinoma Drugs Product Solution and Service
3.7 Date of Enter into Adrenocortical Carcinoma Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Adrenocortical Carcinoma Drugs Breakdown Data by Type
4.1 Global Adrenocortical Carcinoma Drugs Historic Market Size by Type (2016-2021)
4.2 Global Adrenocortical Carcinoma Drugs Forecasted Market Size by Type (2022-2027)
5 Adrenocortical Carcinoma Drugs Breakdown Data by Application
5.1 Global Adrenocortical Carcinoma Drugs Historic Market Size by Application (2016-2021)
5.2 Global Adrenocortical Carcinoma Drugs Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Adrenocortical Carcinoma Drugs Market Size (2016-2027)
6.2 North America Adrenocortical Carcinoma Drugs Market Size by Type
6.2.1 North America Adrenocortical Carcinoma Drugs Market Size by Type (2016-2021)
6.2.2 North America Adrenocortical Carcinoma Drugs Market Size by Type (2022-2027)
6.2.3 North America Adrenocortical Carcinoma Drugs Market Size by Type (2016-2027)
6.3 North America Adrenocortical Carcinoma Drugs Market Size by Application
6.3.1 North America Adrenocortical Carcinoma Drugs Market Size by Application (2016-2021)
6.3.2 North America Adrenocortical Carcinoma Drugs Market Size by Application (2022-2027)
6.3.3 North America Adrenocortical Carcinoma Drugs Market Size by Application (2016-2027)
6.4 North America Adrenocortical Carcinoma Drugs Market Size by Country
6.4.1 North America Adrenocortical Carcinoma Drugs Market Size by Country (2016-2021)
6.4.2 North America Adrenocortical Carcinoma Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Adrenocortical Carcinoma Drugs Market Size (2016-2027)
7.2 Europe Adrenocortical Carcinoma Drugs Market Size by Type
7.2.1 Europe Adrenocortical Carcinoma Drugs Market Size by Type (2016-2021)
7.2.2 Europe Adrenocortical Carcinoma Drugs Market Size by Type (2022-2027)
7.2.3 Europe Adrenocortical Carcinoma Drugs Market Size by Type (2016-2027)
7.3 Europe Adrenocortical Carcinoma Drugs Market Size by Application
7.3.1 Europe Adrenocortical Carcinoma Drugs Market Size by Application (2016-2021)
7.3.2 Europe Adrenocortical Carcinoma Drugs Market Size by Application (2022-2027)
7.3.3 Europe Adrenocortical Carcinoma Drugs Market Size by Application (2016-2027)
7.4 Europe Adrenocortical Carcinoma Drugs Market Size by Country
7.4.1 Europe Adrenocortical Carcinoma Drugs Market Size by Country (2016-2021)
7.4.2 Europe Adrenocortical Carcinoma Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Adrenocortical Carcinoma Drugs Market Size (2016-2027)
8.2 Asia-Pacific Adrenocortical Carcinoma Drugs Market Size by Type
8.2.1 Asia-Pacific Adrenocortical Carcinoma Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Adrenocortical Carcinoma Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Adrenocortical Carcinoma Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Adrenocortical Carcinoma Drugs Market Size by Application
8.3.1 Asia-Pacific Adrenocortical Carcinoma Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Adrenocortical Carcinoma Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Adrenocortical Carcinoma Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Adrenocortical Carcinoma Drugs Market Size by Region
8.4.1 Asia-Pacific Adrenocortical Carcinoma Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Adrenocortical Carcinoma Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Adrenocortical Carcinoma Drugs Market Size (2016-2027)
9.2 Latin America Adrenocortical Carcinoma Drugs Market Size by Type
9.2.1 Latin America Adrenocortical Carcinoma Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Adrenocortical Carcinoma Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Adrenocortical Carcinoma Drugs Market Size by Type (2016-2027)
9.3 Latin America Adrenocortical Carcinoma Drugs Market Size by Application
9.3.1 Latin America Adrenocortical Carcinoma Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Adrenocortical Carcinoma Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Adrenocortical Carcinoma Drugs Market Size by Application (2016-2027)
9.4 Latin America Adrenocortical Carcinoma Drugs Market Size by Country
9.4.1 Latin America Adrenocortical Carcinoma Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Adrenocortical Carcinoma Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Adrenocortical Carcinoma Drugs Market Size (2016-2027)
10.2 Middle East & Africa Adrenocortical Carcinoma Drugs Market Size by Type
10.2.1 Middle East & Africa Adrenocortical Carcinoma Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Adrenocortical Carcinoma Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Adrenocortical Carcinoma Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Adrenocortical Carcinoma Drugs Market Size by Application
10.3.1 Middle East & Africa Adrenocortical Carcinoma Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Adrenocortical Carcinoma Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Adrenocortical Carcinoma Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Adrenocortical Carcinoma Drugs Market Size by Country
10.4.1 Middle East & Africa Adrenocortical Carcinoma Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Adrenocortical Carcinoma Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb Co.
11.1.1 Bristol-Myers Squibb Co. Company Details
11.1.2 Bristol-Myers Squibb Co. Business Overview
11.1.3 Bristol-Myers Squibb Co. Adrenocortical Carcinoma Drugs Introduction
11.1.4 Bristol-Myers Squibb Co. Revenue in Adrenocortical Carcinoma Drugs Business (2016-2021)
11.1.5 Bristol-Myers Squibb Co. Recent Development
11.2 Eli Lilly and Co.
11.2.1 Eli Lilly and Co. Company Details
11.2.2 Eli Lilly and Co. Business Overview
11.2.3 Eli Lilly and Co. Adrenocortical Carcinoma Drugs Introduction
11.2.4 Eli Lilly and Co. Revenue in Adrenocortical Carcinoma Drugs Business (2016-2021)
11.2.5 Eli Lilly and Co. Recent Development
11.3 Laboratoire HRA Pharma SAS
11.3.1 Laboratoire HRA Pharma SAS Company Details
11.3.2 Laboratoire HRA Pharma SAS Business Overview
11.3.3 Laboratoire HRA Pharma SAS Adrenocortical Carcinoma Drugs Introduction
11.3.4 Laboratoire HRA Pharma SAS Revenue in Adrenocortical Carcinoma Drugs Business (2016-2021)
11.3.5 Laboratoire HRA Pharma SAS Recent Development
11.4 Progenics Pharmaceuticals Inc.
11.4.1 Progenics Pharmaceuticals Inc. Company Details
11.4.2 Progenics Pharmaceuticals Inc. Business Overview
11.4.3 Progenics Pharmaceuticals Inc. Adrenocortical Carcinoma Drugs Introduction
11.4.4 Progenics Pharmaceuticals Inc. Revenue in Adrenocortical Carcinoma Drugs Business (2016-2021)
11.4.5 Progenics Pharmaceuticals Inc. Recent Development
11.5 Teva Pharmaceutical Industries Ltd.
11.5.1 Teva Pharmaceutical Industries Ltd. Company Details
11.5.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.5.3 Teva Pharmaceutical Industries Ltd. Adrenocortical Carcinoma Drugs Introduction
11.5.4 Teva Pharmaceutical Industries Ltd. Revenue in Adrenocortical Carcinoma Drugs Business (2016-2021)
11.5.5 Teva Pharmaceutical Industries Ltd. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Adrenocortical Carcinoma Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Targeted therapy
Table 4. Global Adrenocortical Carcinoma Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Adrenocortical Carcinoma Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Adrenocortical Carcinoma Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Adrenocortical Carcinoma Drugs Market Share by Regions (2016-2021)
Table 8. Global Adrenocortical Carcinoma Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Adrenocortical Carcinoma Drugs Market Share by Regions (2022-2027)
Table 10. Adrenocortical Carcinoma Drugs Market Trends
Table 11. Adrenocortical Carcinoma Drugs Market Drivers
Table 12. Adrenocortical Carcinoma Drugs Market Challenges
Table 13. Adrenocortical Carcinoma Drugs Market Restraints
Table 14. Global Adrenocortical Carcinoma Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Adrenocortical Carcinoma Drugs Market Share by Players (2016-2021)
Table 16. Global Top Adrenocortical Carcinoma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Adrenocortical Carcinoma Drugs as of 2020)
Table 17. Ranking of Global Top Adrenocortical Carcinoma Drugs Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Adrenocortical Carcinoma Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Adrenocortical Carcinoma Drugs Product Solution and Service
Table 21. Date of Enter into Adrenocortical Carcinoma Drugs Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Adrenocortical Carcinoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Adrenocortical Carcinoma Drugs Revenue Market Share by Type (2016-2021)
Table 25. Global Adrenocortical Carcinoma Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Adrenocortical Carcinoma Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Adrenocortical Carcinoma Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Adrenocortical Carcinoma Drugs Revenue Market Share by Application (2016-2021)
Table 29. Global Adrenocortical Carcinoma Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Adrenocortical Carcinoma Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Adrenocortical Carcinoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Adrenocortical Carcinoma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Adrenocortical Carcinoma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Adrenocortical Carcinoma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Adrenocortical Carcinoma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Adrenocortical Carcinoma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Adrenocortical Carcinoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Adrenocortical Carcinoma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Adrenocortical Carcinoma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Adrenocortical Carcinoma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Adrenocortical Carcinoma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Adrenocortical Carcinoma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Adrenocortical Carcinoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Adrenocortical Carcinoma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Adrenocortical Carcinoma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Adrenocortical Carcinoma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Adrenocortical Carcinoma Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Adrenocortical Carcinoma Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Adrenocortical Carcinoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Adrenocortical Carcinoma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Adrenocortical Carcinoma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Adrenocortical Carcinoma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Adrenocortical Carcinoma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Adrenocortical Carcinoma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Adrenocortical Carcinoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Adrenocortical Carcinoma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Adrenocortical Carcinoma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Adrenocortical Carcinoma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Adrenocortical Carcinoma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Adrenocortical Carcinoma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 61. Bristol-Myers Squibb Co. Company Details
Table 62. Bristol-Myers Squibb Co. Business Overview
Table 63. Bristol-Myers Squibb Co. Adrenocortical Carcinoma Drugs Product
Table 64. Bristol-Myers Squibb Co. Revenue in Adrenocortical Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 65. Bristol-Myers Squibb Co. Recent Development
Table 66. Eli Lilly and Co. Company Details
Table 67. Eli Lilly and Co. Business Overview
Table 68. Eli Lilly and Co. Adrenocortical Carcinoma Drugs Product
Table 69. Eli Lilly and Co. Revenue in Adrenocortical Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 70. Eli Lilly and Co. Recent Development
Table 71. Laboratoire HRA Pharma SAS Company Details
Table 72. Laboratoire HRA Pharma SAS Business Overview
Table 73. Laboratoire HRA Pharma SAS Adrenocortical Carcinoma Drugs Product
Table 74. Laboratoire HRA Pharma SAS Revenue in Adrenocortical Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 75. Laboratoire HRA Pharma SAS Recent Development
Table 76. Progenics Pharmaceuticals Inc. Company Details
Table 77. Progenics Pharmaceuticals Inc. Business Overview
Table 78. Progenics Pharmaceuticals Inc. Adrenocortical Carcinoma Drugs Product
Table 79. Progenics Pharmaceuticals Inc. Revenue in Adrenocortical Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 80. Progenics Pharmaceuticals Inc. Recent Development
Table 81. Teva Pharmaceutical Industries Ltd. Company Details
Table 82. Teva Pharmaceutical Industries Ltd. Business Overview
Table 83. Teva Pharmaceutical Industries Ltd. Adrenocortical Carcinoma Drugs Product
Table 84. Teva Pharmaceutical Industries Ltd. Revenue in Adrenocortical Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 85. Teva Pharmaceutical Industries Ltd. Recent Development
Table 86. Research Programs/Design for This Report
Table 87. Key Data Information from Secondary Sources
Table 88. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Adrenocortical Carcinoma Drugs Market Share by Type: 2020 VS 2027
Figure 2. Chemotherapy Features
Figure 3. Targeted therapy Features
Figure 4. Global Adrenocortical Carcinoma Drugs Market Share by Application: 2020 VS 2027
Figure 5. Hospital Case Studies
Figure 6. Research institute Case Studies
Figure 7. Clinic Case Studies
Figure 8. Other Case Studies
Figure 9. Adrenocortical Carcinoma Drugs Report Years Considered
Figure 10. Global Adrenocortical Carcinoma Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Adrenocortical Carcinoma Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Adrenocortical Carcinoma Drugs Market Share by Regions: 2020 VS 2027
Figure 13. Global Adrenocortical Carcinoma Drugs Market Share by Regions (2022-2027)
Figure 14. Global Adrenocortical Carcinoma Drugs Market Share by Players in 2020
Figure 15. Global Top Adrenocortical Carcinoma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Adrenocortical Carcinoma Drugs as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Adrenocortical Carcinoma Drugs Revenue in 2020
Figure 17. Global Adrenocortical Carcinoma Drugs Revenue Market Share by Type (2016-2021)
Figure 18. Global Adrenocortical Carcinoma Drugs Revenue Market Share by Type (2022-2027)
Figure 19. North America Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Adrenocortical Carcinoma Drugs Market Share by Type (2016-2027)
Figure 21. North America Adrenocortical Carcinoma Drugs Market Share by Application (2016-2027)
Figure 22. North America Adrenocortical Carcinoma Drugs Market Share by Country (2016-2027)
Figure 23. United States Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Adrenocortical Carcinoma Drugs Market Share by Type (2016-2027)
Figure 27. Europe Adrenocortical Carcinoma Drugs Market Share by Application (2016-2027)
Figure 28. Europe Adrenocortical Carcinoma Drugs Market Share by Country (2016-2027)
Figure 29. Germany Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Adrenocortical Carcinoma Drugs Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Adrenocortical Carcinoma Drugs Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Adrenocortical Carcinoma Drugs Market Share by Region (2016-2027)
Figure 39. China Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Adrenocortical Carcinoma Drugs Market Share by Type (2016-2027)
Figure 47. Latin America Adrenocortical Carcinoma Drugs Market Share by Application (2016-2027)
Figure 48. Latin America Adrenocortical Carcinoma Drugs Market Share by Country (2016-2027)
Figure 49. Mexico Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Adrenocortical Carcinoma Drugs Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Adrenocortical Carcinoma Drugs Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Adrenocortical Carcinoma Drugs Market Share by Country (2016-2027)
Figure 55. Turkey Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Adrenocortical Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Bristol-Myers Squibb Co. Revenue Growth Rate in Adrenocortical Carcinoma Drugs Business (2016-2021)
Figure 59. Eli Lilly and Co. Revenue Growth Rate in Adrenocortical Carcinoma Drugs Business (2016-2021)
Figure 60. Laboratoire HRA Pharma SAS Revenue Growth Rate in Adrenocortical Carcinoma Drugs Business (2016-2021)
Figure 61. Progenics Pharmaceuticals Inc. Revenue Growth Rate in Adrenocortical Carcinoma Drugs Business (2016-2021)
Figure 62. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Adrenocortical Carcinoma Drugs Business (2016-2021)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed